Skip to main content

Table 6 Medication groups used for treating hypertensive T2D and non-T2D participants respectively

From: Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies

ATC group

Use in treated participants with T2D

Use in treated participants without T2D

Comment

  

N = 760 (%) single or in combination with other preparations

as spreparation/ATC group

N = 3852 (%) single or in combination with other preparations

as single preparation/ATC group

 

C02

Anti-hypertensives

9.47

2.11

8.00

2.78

 

C03

Diuretics

29.47

2.50

17.29*

2.52

not ideal as first line treatment since they can worsen glucose and lipid levels

C04

Peripheral vasodilators

4.21

0.13

2.65*

0.31

 

C07

Beta blocking agents

44.74

8.82

52.23*

23.81*

best used as second- or third-line treatments in T2D, more efficacious in younger patients (55–60 years), not for asthma patients, because of bronchoconstrictive effects, promote weight gain, may mask hypoglycaemia

C08

Calcium channel blockers

33.68

5.79

27.13*

7.84*

not recommended as first-line and single treatment

C09

Agents acting on the renin-angiotensin system

68.95

20.53

51.43*

18.98

recommended as first-line treatment, reduce the risk for renal end points

  1. * p for the difference between participants with T2D and participants without T2D <0.05.
  2. Anti-hypertensive medication in participants who were classified as non-hypertensive or unknown was not considered in this analysis, assuming that they used these agents for different indications.